Every 10-Q that MaxCyte, Inc. (MXCT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MXCT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MXCT filings page.
MaxCyte, Inc. reported lower revenue and a smaller loss for the quarter ended June 30, 2026. Q2 revenue was $7.3 million, down from $8.5 million a year earlier, with core revenue falling 21% while SPL milestones and royalties more than doubled. Gross margin declined to 77%.
Operating expenses fell sharply to $15.8 million from $21.2 million, driven by a 2025 workforce reduction and lower stock-based compensation, partly offset by a $1.6 million write-off of abandoned asset-acquisition costs and a $0.6 million asset impairment. Net loss improved to $8.9 million in Q2 and $13.6 million for the first half. The company used $12.8 million in operating cash in the first six months, ending June 30, 2026 with $15.0 million in cash and $126.9 million in short- and long-term investments, no debt, and $158.8 million in stockholders’ equity. MaxCyte began a share repurchase program, buying 1.3 million shares for $1.5 million in the first half and an additional 2.9 million shares for $4.0 million after quarter-end.
MaxCyte, Inc. reported first-quarter 2026 results showing lower revenue but a smaller loss as it reduced operating expenses. Revenue was $9.7 million versus $10.4 million a year earlier, driven by weaker core product and license sales, partly offset by higher milestone and royalty revenue.
Core revenue fell to $6.2 million, mainly from lower processing assembly and license revenue, while Strategic Platform License milestones and royalties rose to $3.4 million. Gross margin remained high at 84%. The net loss narrowed to $4.8 million from $10.3 million as research, sales, and administrative costs declined.
MaxCyte ended March 31, 2026 with cash and cash equivalents of $14.6 million, short-term investments of $92.3 million, and long-term investments of $40.8 million. Management states that existing cash, investments, and operating cash flows are expected to fund operations for at least 12 months while it continues investing in its ExPERT cell engineering platform and new products such as the ExPERT DTx.
MaxCyte, Inc. reported lower quarterly results as it navigates restructuring and integration of a recent acquisition. For the three months ended September 30, 2025, revenue was $6.8 million versus $8.2 million a year ago, driven by declines in instruments, consumables, and license activity. Net loss was $12.4 million compared to $11.6 million last year.
Nine-month revenue was $25.7 million versus $29.9 million in 2024, with operating cash use of $31.7 million. The company recorded $3.1 million in restructuring expense tied to a workforce reduction plan. Cash and cash equivalents were $13.0 million, with short‑term investments of $92.8 million and non‑current investments of $52.3 million as of September 30, 2025.
Customer concentration remained high: one customer represented 28% of Q3 revenue and 51% of accounts receivable. The SeQure Dx acquisition added capabilities in gene‑editing assessment; in Q3 it contributed $0.1 million of revenue and a $1.8 million net loss. Shares outstanding were 106.7 million as of November 7, 2025.